Why the study?
Does a single intravenous bolus of flecainide improve conversion to sinus rhythm in patients with recent-onset atrial fibrillation?
Does a single intravenous bolus of flecainide improve conversion to sinus rhythm in patients with recent-onset atrial fibrillation?
A single intravenous bolus of flecainide is highly effective for cardioverting recent-onset atrial fibrillation (especially <72 hours duration) to sinus rhythm without significant side effects.
Answers are grounded in this paper and cite their sources.
May support IV flecainide for recent-onset AF conversion; hypothesis-generating and requires randomized confirmation.
Twenty-eight patients with atrial fibrillation of less than 1 month's duration were given a single intravenous bolus of flecainide (2 mg/kg). Nineteen patients (68%) were successfully converted to sinus rhythm. Of the 19 patients with atrial fibrillation of less than 72 hours duration, 18 (95%) were successfully converted. Failure to cardiovert was associated with cardiomegaly on chest X-ray and larger left atrial diameter measured echocardiographically. Of the 9 patients who failed to convert, 2 had biochemical evidence of thyrotoxicosis and chronic obstructive pulmonary disease. Of the 19 patients successfully cardioverted, the atrial fibrillation complicated acute myocardial infarction in 3 cases and a pulmonary embolism in one. Six cases occurred post-operatively and in 3 out of 6 the patient was ventilated. No side effects were observed. The use of intravenous flecainide should avoid the need for electrical DC conversion even in sick patients. Failure of conversion is associated with covert underlying predisposing factors and duration of atrial fibrillation of more than 72 hours.
No takes yet. Share an insight, caveat, or question.
Carr et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: